**Product Information**

**Doravirine**

*Item No. 26405*

---

**CAS Registry No.:** 1338225-97-0  
**Formal Name:** 3-chloro-5-[[1-[[4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl]methyl]-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]-benzonitrile  
**Synonym:** MK-1439  
**MF:** C_{17}H_{11}ClF_{3}N_{5}O_{3}  
**FW:** 425.8  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥2 years

*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

---

**Laboratory Procedures**

Doravirine is supplied as a solid. A stock solution may be made by dissolving the doravirine in the solvent of choice. Doravirine is soluble in the organic solvent DMSO, which should be purged with an inert gas. It is also slightly soluble in methanol.

---

**Description**

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV reverse transcriptase (IC_{50} = 11 nM).\(^1\) It inhibits the spread of wild-type HIV and K103N, Y181C, and K103N/Y181C mutant HIV strains in cells cultured with 50% normal human serum (IC_{95} = 19, 42, 25, and 54 nM, respectively). Formulations containing doravirine have been used in the treatment of HIV-1 infection.

---

**Reference**